

**Patent Status:** HHS Reference No. E-175-2011/0 —Research Tool. Patent protection is not being pursued for this technology.

**Licensing Status:** Available for licensing under a Biological Materials License Agreement.

**Licensing Contact:** Betty B. Tong, PhD; 301-594-6565; tongb@mail.nih.gov.

**Collaborative Research Opportunity:** The NIEHS Laboratory of Signal Transduction is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these mice or other strains derived from them, or cells or other reagents derived from them. Please contact Dr. Elizabeth Denholm ([denholme@niehs.nih.gov](mailto:denholme@niehs.nih.gov)) in the NIEHS Office of Technology Transfer, or the Inventor Dr. Perry Blackshear ([black009@niehs.nih.gov](mailto:black009@niehs.nih.gov)) for more information.

#### **Inhibitors of Human Apurinic/ Apyrimidinic Endonuclease 1 (APE1), an Anticancer Drug Target**

**Description of Technology:** APE1 is the primary mammalian enzyme responsible for the removal of abasic (AP sites) in DNA and functions as part of the base excision DNA repair pathway (BER). BER is instrumental in the repair of DNA damage caused by DNA alkylating agents (e.g. many cancer chemotherapeutics). APE1 has been shown to be overexpressed in cancer cells. It has been postulated that APE1 would be an attractive target in anti-cancer treatment paradigms; preclinical and clinical data confirm that APE1 is a valid anticancer drug target.

To date, only one APE1 small molecule inhibitor has progressed to clinical trials (methoxyamine hydrochloride), and this compound inhibits a wide range of repair processes, which could result in undesired side-effects. The NIH inventors now report the discovery of a novel APE1 small molecule inhibitor, which exhibits potent *in vitro* activity, potentiates the cytotoxicity of DNA damaging agents (alkylators methylmethane sulfonate and Temozolomide), results in the accumulation of AP sites, and has favorable pharmacokinetic properties. The inventors plan to carry out further studies in mouse tumor xenograft models.

**Applications:** Cancer therapeutics as single agent as well as in combination therapy.

**Development Status:** *In vivo* pharmacokinetics data on lead compounds available.

**Inventors:** David J. Maloney, *et al.* (NHGRI).

**Publication:** Manuscript submitted.  
**Patent Status:** U.S. Provisional Patent Application No. 61/480,145 filed April 28, 2011 (HHS Reference No. E-094-2011/0-US-01).

**Licensing Status:** Available for licensing.

**Licensing Contact:** Betty B. Tong, PhD; 301-594-6565; tongb@mail.nih.gov.

**Collaborative Research Opportunity:** The NIH Center for Translational Therapeutics, NHGRI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the above technology. Please contact Lili Portilla, Acting Director of Technology Transfer and Partnerships, NCTT at [Lilip@nih.gov](mailto:Lilip@nih.gov) for more information.

Dated: July 1, 2011.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2011-17227 Filed 7-7-11; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Center on Minority and Health Disparities; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Center on Minority Health and Health Disparities Special, Emphasis Panel, U24 Grant Review.

**Date:** July 11-12, 2011.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

**Contact Person:** Robert Nettey, M.D., Chief, Scientific Review Officer, National Institute on Minority Health and Health Disparities, 6707 Democracy Boulevard, Suite 800,

Bethesda, MD 20892. (301) 496-3996. [netteyr@mail.nih.gov](mailto:netteyr@mail.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** National Center on Minority Health and Health Disparities Special Emphasis Panel, R13 Review.

**Date:** July 13, 2011.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892. (Virtual Meeting.)

**Contact Person:** Robert Nettey, M.D., Chief, Scientific Review Officer, National Institute on Minority Health and Health Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892. (301) 496-3996. [netteyr@mail.nih.gov](mailto:netteyr@mail.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Dated: July 1, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-17225 Filed 7-7-11; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Center for Research Resources; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Center for Research Resources Special Emphasis Panel, NCCR Animal Resource.

**Date:** July 28, 2011.

**Time:** 1 to 2 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health/NCCR/OR, Democracy 1, 6701 Democracy Blvd., 1078, Bethesda, MD 20892.

**Contact Person:** Lee Warren Slice, PhD, Scientific Review Officer, Office of Review, National Center for Research Resources, 6701